<DOC>
	<DOC>NCT01411228</DOC>
	<brief_summary>A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to &lt;18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase) or PB-06-005 (na√Øve treatment with taliglucerase alfa).</brief_summary>
	<brief_title>A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Successful completion of Protocol PB06002 or PB06005 The subject, parent(s) or legal guardian(s) signs an informed consent and/or assent Currently taking another investigational drug for any condition. Presence of neurological signs and symptoms characteristic of Gaucher disease with complex neuronopathic features other than longstanding oculomotor gaze palsy. Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gaucher disease</keyword>
	<keyword>pediatrics</keyword>
</DOC>